working 24/7 for truth and honesty
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
the publication does not mean the results are independently validated sorry
LOL LOL no just reporting the news
I don’t know I don’t follow it
Wow good pps tonight $2.50. Oh wait
….,,,,,,,,
really??? i didnt see that. LOL LOL
A classic pump and dump but not as well executed as some, should have brought it down a little less, well maybe tomorrow LOL LOL
they are better journalists and know a scam when they see it
total nonsense
I never said I did. LOL
won? what?? I may have missed the PR about FDA approval LOL LOL
say, good news nwbo got an abstract . but, wait.......
https://finance.yahoo.com/news/novocure-announces-25-abstracts-tumor-130000256.html
LOL no I saw that, but of course it doesnt answer the questions, hmmmmmmmmm
unless I missed it there is no mention of nwbo as the supplier of DCVAX. wow that could be huge LOL
Thanks, but that does not answer the questions
did nwbo manufacture dccrap??? I may have missed that in the paper. Does nwbo even own dccrap????
https://edhub.ama-assn.org/jn-learning/audio-player/18738384
LL did a very nice job in the interview, but curiously, made no mention of NWBO.
until they read the paper, then.............. lol lol
it is dr Lowenstein by the way
LOL a podiatrist???? might as well ask your car mechanic to perform an appendectomy
ah nefarious??? wow, this is getting interesting LOL LOL
2011???? what is the relevance today
we know all that
ah so that argument is that only positive comments are truth, all the rest are not. LOL LOL
LOL august 2022
I have presented a couple of published papers, from unpaid oncologists LOL
that assumes peer review is over , and of course we dont know that
no and I have dozens of oncology experts that say no it wasnt
How do you rip off the edges of online papers lol
the name is Dr Lowenstein
I know I see an abstract here from SNO that is clearly wrong LOL
what list do you want JIM, always happy to provide
LOL I understand why
the name is Dr Lowenstein and no I am not recommending , these are complex discussions
I am keeping a running total of oncologists who are skeptical of the miracle drug. Hey maybe I should make a chart ? lol lol
Cancers (Basel). 2022 Aug; 14(16): 4023.
Published online 2022 Aug 20. doi: 10.3390/cancers14164023
PMCID: PMC9406905
PMID: 36011015
LOL LOL August 2022
hmmmm this is interesting
The phase 3 DCVax trial (NCT00045968) investigated the impact of DCVax-L in addition to SOC (surgical resection and chemoradiotherapy) for newly diagnosed GBM patients. Due to the cross-over study design, nearly 90% of the patients in this study received DCVax-L, making an interpretation of the survival outcome challenging. In the overall intent to treat the patient population (investigational arm + control arm), the mOS was estimated to be 23.1 months. This study has benchmarked these findings to historical controls but has not yet evaluated its primary endpoint of PFS [62]. A recent phase 1 trial focused on an autologous DC vaccine pulsed with GBM stem-like cell line lysate, which was shown to be tolerable (NCT02010606). Further results are pending [63].
nonsense, we already know LOL
interesting, note the primary endpoints in the UCLA study
Outcome Measures
Go to sections
Primary Outcome Measures :
Cell cycle-related signature [ Time Frame: Up to 6 years ]
Expansion of T cell receptor (TCR) clones [ Time Frame: Up to 6 years ]
Two-sample T-test with Bonferroni adjustment will be used to compare the increase number of expanded TCR clones after dendritic cell (DC) vaccination with PD-1 blockade in Group A versus (vs) DC vaccination with a placebo in Group B.
Incidence of adverse events (AEs) [ Time Frame: Up to 30 days post treatment ]
Adverse events will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. All patients who receive any amount of pembrolizumab/placebo or ATL-DC vaccination will be evaluable for toxicity, serious adverse events (SAEs), and events of clinical interest (ECIs).
OS and PFS Not endpoints
good they are using Bonferroni , I wonder if they did that in the p3????????